


Ingested Inhaled

Efficiency that matters to labs. Information that matters to clinicians



Allergy* is associated with symptoms ranging from mild and annoying to severe and life-threatening, typically appearing within minutes of allergen exposure.

Diagnosis can be challenging—symptoms often overlap with other conditions and may not always manifest despite sensitization.

MosaiQ AllergyPlex COMBO is a single-use multiplex microarray featuring a panel of common ingested and inhaled allergens, plus a CCD flag. When run on the automated MosaiQ system, clinically actionable insights are delivered fast and efficiently—empowering clinicians with the information they need when considering possible diagnoses

^{*}Type I hypersensitivity reaction

Fast, Easy, Comprehensive MosaiQ AllergyPlex® COMBO

With up to 30% of the global population affected, **IgE-mediated allergic disorders** are on the rise across all age groups¹—driving demand for fast, efficient, and comprehensive diagnostic solutions.

At AliveDx, we're transforming allergy diagnostics with multiplex technology that delivers clinically relevant results fast - meaning clinicians have the information they need to make accurate diagnoses, enabling appropriate treatment initiation sooner.





Precise Quantification: Provides results by class and arbitrary units (kU_A/L) with traceability to the WHO standard.



Reduces hands-on time and storage space with ready to use, concentrated onboard reagents and buffers.



Saves time while avoiding human errors

with a standardized master curve embedded into RFID* tags, included with all reagents and microarrays.



Shares key reagents with other panels, enabling combined autoimmunity, allergy, and further testing.

^{*} RFID: Radio Frequency Identification







• Patients sample in,

result out in one single step

QC and calibration embedded

Simple Workflow





- Results within one day
- One sample tube (low volume) for multiple tests



Actionable Insights

- Panels help streamline clinical decision-making for physicians
- Comprehensive panels simplifly complex testing pathways

1. Edwards-Salmon, S.E. et al. Increasing Prevalence of Allergic Disease and Its Impact on Current Practice. Curr Otorhinolaryngol Rep 10, 278–284 (2022).



©AliveDx Suisse SA. 2025. The AliveDx logo, AliveDx, MosaiQ, MosaiQ AllergyPlex, and AllergyPlex are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance. This product is not currently available in the USA, cleared or approved by the U.S. Food and Drug Administration (FDA) for clinical use.

